Developer docs
API playgroundTry for free, no card

Search company profiles

BioAge Labs

Full company profile

uuid000026w

Namestring
BioAge Labs
Legal namestring
BioAge Labs, Inc.
Websiteurl
bioagelabs.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

BioAge Labs, Inc. is a clinical-stage biotechnology company developing therapeutics that target the biology of human aging to treat obesity and age-related metabolic diseases. The company is headquartered in Emeryville, California, was co-founded in 2015 by Kristen Fortney, PhD, and Eric Morgen, MD, and has been listed on Nasdaq under the ticker BIOA since its October 2024 initial public offering. BioAge's pipeline is anchored by BGE-102, an oral, brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel binding site; BGE-102 demonstrated an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) in Phase 1 trials and entered a 160-adult Phase 2 proof-of-concept trial (QUELL-CV) in June 2026 for cardiovascular risk reduction, with a planned expansion into diabetic macular edema. A second program, an apelin receptor (APJ) agonist, is in preclinical development as an exercise-mimetic to enhance incretin-driven weight loss in obesity, with IND submission anticipated by year-end 2026.

BioAge's core technology is a human-first discovery platform that applies AI/ML-enabled data science to proprietary longitudinal multi-omics data captured over decades from human aging cohorts, supplemented by an in-house translational aging core in naturally aged mice for target validation. The platform has been externally validated through research collaborations with Novartis (a $550M collaboration) and Eli Lilly (Lilly Chorus combination study of azelaprag with Zepbound in obesity), and by a data partnership with Norway's HUNT Biobank. The pipeline also includes two undisclosed discovery-stage cardiometabolic programs.

BioAge is pre-revenue with no marketed products and no disclosed product pricing; future revenue is expected to come from licensing, royalty, and partnership milestone payments rather than direct sales, supported by a cash position of approximately $390M as of Q1 2026 and no long-term debt, providing a stated runway through 2029. The company is led by co-founder/CEO Kristen Fortney, PhD, alongside a leadership team that has contributed to 95+ regulatory approvals, and its board includes representation from major investors Sofinnova Investments, Longitude Capital, and VZVC.

Short descriptiontext

BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aging biology therapeutics, metabolic disease drug discovery, multi-omics AI platform, obesity cardiometabolic therapies, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Metabolic Disease Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1None (Pre-revenue)
TypeLicensing Royalties
Description

BioAge Labs is a clinical-stage biopharmaceutical company with no current product revenue. Revenue growth is not expected for years as the drug candidates remain in early clinical development stages. Future potential revenue streams could include licensing/royalty deals, partnership milestone payments, and ultimately product sales if drug candidates are approved.

seekingalpha.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1On Translating Aging
Description

A podcast sponsored by BioAge Labs featuring conversations with researchers, entrepreneurs, and investors moving longevity science from the lab to the clinic.

bioagelabs.com
Core offering1 text field

BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at 60mg and 120mg doses of BGE-102 in Phase 1 trial (14-21 days)
+3 more records
Product overview1 text field

BioAge Labs offers a platform-plus-pipeline architecture. The core "Discovery Platform" is a proprietary human-first, multi-omics analysis engine that uses AI/ML to identify molecular drivers of metabolic aging. This platform powers a clinical-stage pipeline of drug candidates: the lead program BGE-102 (an oral, brain-penetrant NLRP3 inhibitor in Phase 1/Phase 2 for cardiovascular risk and diabetic macular edema), the APJ agonist program (oral and parenteral apelin receptor agonists in preclinical/IND-enabling stage for obesity as exercise mimetics to enhance incretin-driven weight loss), and additional earlier discovery-stage programs (Program 1 and Program 2, undisclosed cardiometabolic targets). The platform is externally validated through ongoing research collaborations with Novartis and Eli Lilly.

Product and service3 records
1BGE-102 (oral NLRP3 inhibitor)
CategoryLead clinical-stage drug candidate (NLRP3 inhibitor)
Description

Oral, potent, highly brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel structure and binding site; lead indications are cardiovascular risk reduction and diabetic macular edema. As of mid-2026, BGE-102 is in a Phase 2 proof-of-concept trial (QUELL-CV) following positive Phase 1 data showing up to 86% median reductions in high-sensitivity C-reactive protein.

2APJ Agonist Program
CategoryPreclinical drug candidate (APJ agonist / exercise mimetic)
Description

Apelin receptor (APJ) agonist program with both oral and long-acting injectable (SQ QW) formulations functioning as an exercise mimetic for obesity. In preclinical models, agonism of APJ has the potential to double weight loss and fully restore body composition when combined with an incretin.

3Azelaprag (oral apelin receptor agonist)
CategoryClinical-stage drug candidate (azelaprag)
Description

Oral apelin receptor agonist being advanced in combination with Eli Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases, conducted through Lilly's Chorus organization.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1HUNT Biobank (Norway)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

BioAge partners with Norway's HUNT Biobank to study human longevity markers and feed its multi-omics discovery platform. The biobank data underpins the company's human-first approach to identifying molecular pathways that drive aging.

time.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-10
Description

Novartis has a $550M collaboration with BioAge to advance age-related therapies. BioAge's discovery platform is validated by ongoing research collaborations with Novartis, supporting development of novel therapies targeting aging biology.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-10
Description

BioAge sponsors and distributes the 'On Translating Aging' podcast through Apple Podcasts and Spotify, expanding the reach of its longevity thought leadership content to global audiences.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-02-13
Description

BioAge is collaborating with Eli Lilly to advance azelaprag in combination with Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases. The collaboration is conducted through Lilly's Chorus organization, with BioAge's lead program azelaprag entering Phase 2 trials in combination with Zepbound. Lilly's support extends to participation in the Series D financing via Lilly Ventures.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral NLRP3 inhibitors (including VTX3232), directly competing with BioAge's BGE-102 in the same target, similar inflammatory disease indications, and overlapping patient populations.

TypeDirect peer
Description

AI-enabled clinical-stage drug discovery company combining high-throughput biology with machine learning. Highly comparable in business model (platform-plus-pipeline), public-market status, and reliance on computational approaches to identify novel targets.

TypeEmerging player
Description

Machine-learning-driven drug discovery company focused on metabolic disease and neuroscience; overlaps with BioAge in combining proprietary human data with AI/ML to identify drug targets, particularly in metabolic indications.

TypeDirect peer
Description

Computational drug discovery company combining physics-based modeling with machine learning to accelerate small-molecule discovery; comparable in applying computational platforms to drive pipeline asset generation in a publicly traded biotech.

TypeDirect peer
Description

Clinical-stage biotech developing oral small-molecule therapies for metabolic diseases including obesity (e.g., oral GLP-1 agonist); directly comparable therapeutic area, modality and obesity / cardiometabolic strategy.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for metabolic and endocrine disorders, with a notable obesity candidate (VK2735); comparable stage, target indication (obesity/metabolic), and small-molecule / peptide approach.

TypeDirect peer
Description

Commercial/specialty biopharma in metabolic liver disease (resmetirom for MASH/NASH); comparable in addressing inflammation-driven metabolic disease with small-molecule therapies and operating in overlapping patient populations.

TypeEmerging player
Description

Well-capitalized private biotech focused on cellular rejuvenation and aging biology; directly comparable in mission to translate aging biology into therapeutics and in leveraging proprietary human biology datasets.

TypeEmerging player
Description

Clinical-stage biotech developing senolytic and anti-aging therapeutics; overlaps with BioAge in targeting molecular mechanisms of aging to treat age-related metabolic and inflammatory diseases.

TypeBroad incumbent
Description

Alphabet-backed R&D organization focused on aging biology and age-related disease; comparable in scientific mission and multi-omics approach to understanding metabolic aging, though with substantially greater resources.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioAge Labs

Metabolic Disease Therapeuticsbioagelabs.com

BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.

What BioAge Labs does

BioAge Labs, Inc. is a clinical-stage biotechnology company developing therapeutics that target the biology of human aging to treat obesity and age-related metabolic diseases. The company is headquartered in Emeryville, California, was co-founded in 2015 by Kristen Fortney, PhD, and Eric Morgen, MD, and has been listed on Nasdaq under the ticker BIOA since its October 2024 initial public offering. BioAge's pipeline is anchored by BGE-102, an oral, brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel binding site; BGE-102 demonstrated an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) in Phase 1 trials and entered a 160-adult Phase 2 proof-of-concept trial (QUELL-CV) in June 2026 for cardiovascular risk reduction, with a planned expansion into diabetic macular edema. A second program, an apelin receptor (APJ) agonist, is in preclinical development as an exercise-mimetic to enhance incretin-driven weight loss in obesity, with IND submission anticipated by year-end 2026.

BioAge's core technology is a human-first discovery platform that applies AI/ML-enabled data science to proprietary longitudinal multi-omics data captured over decades from human aging cohorts, supplemented by an in-house translational aging core in naturally aged mice for target validation. The platform has been externally validated through research collaborations with Novartis (a $550M collaboration) and Eli Lilly (Lilly Chorus combination study of azelaprag with Zepbound in obesity), and by a data partnership with Norway's HUNT Biobank. The pipeline also includes two undisclosed discovery-stage cardiometabolic programs.

BioAge is pre-revenue with no marketed products and no disclosed product pricing; future revenue is expected to come from licensing, royalty, and partnership milestone payments rather than direct sales, supported by a cash position of approximately $390M as of Q1 2026 and no long-term debt, providing a stated runway through 2029. The company is led by co-founder/CEO Kristen Fortney, PhD, alongside a leadership team that has contributed to 95+ regulatory approvals, and its board includes representation from major investors Sofinnova Investments, Longitude Capital, and VZVC.

BioAge Labs firmographics

Firmographics
Name
BioAge Labs
Legal name
BioAge Labs, Inc.
Website
https://bioagelabs.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.
Ownership category
akta.pro rank

BioAge Labs industry classification

Industry
Product category
Metabolic Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Aging biology therapeutics
  • Metabolic disease drug discovery
  • Multi-omics AI platform
  • Obesity cardiometabolic therapies
  • Clinical-stage biopharmaceuticals

Where BioAge Labs is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioAge Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. None (Pre-revenue): BioAge Labs is a clinical-stage biopharmaceutical company with no current product revenue. Revenue growth is not expected for years as the drug candidates remain in early clinical development stages. Future potential revenue streams could include licensing/royalty deals, partnership milestone payments, and ultimately product sales if drug candidates are approved.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

BioAge Labs product offering

Product offering

Core offering

BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.

Product overview

BioAge Labs offers a platform-plus-pipeline architecture. The core "Discovery Platform" is a proprietary human-first, multi-omics analysis engine that uses AI/ML to identify molecular drivers of metabolic aging. This platform powers a clinical-stage pipeline of drug candidates: the lead program BGE-102 (an oral, brain-penetrant NLRP3 inhibitor in Phase 1/Phase 2 for cardiovascular risk and diabetic macular edema), the APJ agonist program (oral and parenteral apelin receptor agonists in preclinical/IND-enabling stage for obesity as exercise mimetics to enhance incretin-driven weight loss), and additional earlier discovery-stage programs (Program 1 and Program 2, undisclosed cardiometabolic targets). The platform is externally validated through ongoing research collaborations with Novartis and Eli Lilly.

Differentiator

Problem solved

Functional benefit

Brands

  • On Translating Aging: A podcast sponsored by BioAge Labs featuring conversations with researchers, entrepreneurs, and investors moving longevity science from the lab to the clinic.

Products and services

  • BGE-102 (oral NLRP3 inhibitor) Oral, potent, highly brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel structure and binding site; lead indications are cardiovascular risk reduction and diabetic macular edema. As of mid-2026, BGE-102 is in a Phase 2 proof-of-concept trial (QUELL-CV) following positive Phase 1 data showing up to 86% median reductions in high-sensitivity C-reactive protein.
  • APJ Agonist Program Apelin receptor (APJ) agonist program with both oral and long-acting injectable (SQ QW) formulations functioning as an exercise mimetic for obesity. In preclinical models, agonism of APJ has the potential to double weight loss and fully restore body composition when combined with an incretin.
  • Azelaprag (oral apelin receptor agonist) Oral apelin receptor agonist being advanced in combination with Eli Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases, conducted through Lilly's Chorus organization.

Quantifiable outcome

  • 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at 60mg and 120mg doses of BGE-102 in Phase 1 trial (14-21 days)
  • +3 more outcomes

Companies that use BioAge Labs

Customer profile

Segments4 records

Ideal customer profiles2 records

BioAge Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

BioAge Labs partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

  • HUNT Biobank (Norway)coreStrategic or Co-development Partner · 7 January 2026BioAge partners with Norway's HUNT Biobank to study human longevity markers and feed its multi-omics discovery platform. The biobank data underpins the company's human-first approach to identifying molecular pathways that drive aging.
  • NovartisflagshipStrategic or Co-development Partner · 10 July 2025Novartis has a $550M collaboration with BioAge to advance age-related therapies. BioAge's discovery platform is validated by ongoing research collaborations with Novartis, supporting development of novel therapies targeting aging biology.
  • Apple Podcasts and Spotify (Podcast distribution)minorChannel Partner/ Reseller/ Distributor · 10 October 2024BioAge sponsors and distributes the 'On Translating Aging' podcast through Apple Podcasts and Spotify, expanding the reach of its longevity thought leadership content to global audiences.
  • Eli LillyflagshipStrategic or Co-development Partner · 13 February 2024BioAge is collaborating with Eli Lilly to advance azelaprag in combination with Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases. The collaboration is conducted through Lilly's Chorus organization, with BioAge's lead program azelaprag entering Phase 2 trials in combination with Zepbound. Lilly's support extends to participation in the Series D financing via Lilly Ventures.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

BioAge Labs competitors and assessment

Company assessment

Direct peers

  • Ventyx Biosciences: Clinical-stage biotech developing oral NLRP3 inhibitors (including VTX3232), directly competing with BioAge's BGE-102 in the same target, similar inflammatory disease indications, and overlapping patient populations.
  • Recursion Pharmaceuticals: AI-enabled clinical-stage drug discovery company combining high-throughput biology with machine learning. Highly comparable in business model (platform-plus-pipeline), public-market status, and reliance on computational approaches to identify novel targets.
  • Schrödinger, Inc. Computational drug discovery company combining physics-based modeling with machine learning to accelerate small-molecule discovery; comparable in applying computational platforms to drive pipeline asset generation in a publicly traded biotech.
  • Structure Therapeutics: Clinical-stage biotech developing oral small-molecule therapies for metabolic diseases including obesity (e.g., oral GLP-1 agonist); directly comparable therapeutic area, modality and obesity / cardiometabolic strategy.
  • Viking Therapeutics: Clinical-stage biotech developing therapies for metabolic and endocrine disorders, with a notable obesity candidate (VK2735); comparable stage, target indication (obesity/metabolic), and small-molecule / peptide approach.
  • Madrigal Pharmaceuticals: Commercial/specialty biopharma in metabolic liver disease (resmetirom for MASH/NASH); comparable in addressing inflammation-driven metabolic disease with small-molecule therapies and operating in overlapping patient populations.

Emerging players

  • Insitro: Machine-learning-driven drug discovery company focused on metabolic disease and neuroscience; overlaps with BioAge in combining proprietary human data with AI/ML to identify drug targets, particularly in metabolic indications.
  • Altos Labs: Well-capitalized private biotech focused on cellular rejuvenation and aging biology; directly comparable in mission to translate aging biology into therapeutics and in leveraging proprietary human biology datasets.
  • Unity Biotechnology: Clinical-stage biotech developing senolytic and anti-aging therapeutics; overlaps with BioAge in targeting molecular mechanisms of aging to treat age-related metabolic and inflammatory diseases.

Broad incumbents

  • Calico Life Sciences (Alphabet): Alphabet-backed R&D organization focused on aging biology and age-related disease; comparable in scientific mission and multi-omics approach to understanding metabolic aging, though with substantially greater resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

BioAge Labs social profiles

Digital presence

BioAge Labs compliance and trust

Trust signal

Compliance3 records

BioAge Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioAge Labs leadership team

Management profile

Number of profiles

Profiles13 records

BioAge Labs funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioAge Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAge Labs

What does BioAge Labs do?

BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.

Is BioAge Labs a public or private company?

BioAge Labs is a public company. It is classified as public and is currently operating.

When was BioAge Labs founded?

BioAge Labs was founded in 2015. It employs 101 to 250 people.

Where is BioAge Labs based?

BioAge Labs is headquartered in Emeryville, United States, in the North America region.

How does BioAge Labs make money?

One revenue line is on record: none (Pre-revenue).

Who are BioAge Labs's main competitors?

Direct peers on record are Ventyx Biosciences, Recursion Pharmaceuticals, Schrödinger, Inc., Structure Therapeutics, Viking Therapeutics and Madrigal Pharmaceuticals. Emerging players are Insitro, Altos Labs and Unity Biotechnology. Calico Life Sciences (Alphabet) is listed as a broad incumbent.

Does BioAge Labs have an API?

No public API is recorded for BioAge Labs.

What industry is BioAge Labs in?

BioAge Labs's product category is Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCitigroup maintains Bioage Labs at Buy, lowers price target to $20 from $21Citigroup maintained Bioage Labs at Buy and lowered its price target to $20 from $21, a 4.8% decrease. The target implies an upside of 292.2% from the Nov 17 close of $5.10.Seeking AlphaBioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 TranscriptBioAge Labs presented at the UBS Global Biopharma Conference, highlighting its lead program BGE-102, an oral NLRP3 inhibitor. Phase I data showed up to 98% IL-1beta inhibition with placebo-like tolerability. The company is now running a Phase II trial, QUELL-CV, to assess dose response.Investing.comBioAge Labs at UBS conference: pivots BGE-102 toward eye diseaseBioAge Labs pivoted its lead NLRP3 inhibitor BGE-102 toward diabetic macular edema at the UBS conference, citing Novo Nordisk's failed ZEUS trial as a setback for cardiovascular outcomes. The company has about $350 million in cash, expecting to fund programs through 2029, and plans an APJ agonist IND filing by end of 2024.Defense WorldSol-Gel Technologies (NASDAQ:SLGL) vs. BioAge Labs (NASDAQ:BIOA) Critical ContrastSol-Gel Technologies and BioAge Labs are compared on profitability, institutional ownership, and analyst ratings. Sol-Gel has higher revenue and earnings but lower analyst upside, while BioAge has higher probable upside. Sol-Gel beats BioAge on 8 of 15 factors.TradingViewBioAge Labs, Inc. Stock 12‑Month Price Target Raised to $29.5, Implies 432% UpsideAnalysts' average price target for BioAge Labs, Inc. rose to $29.5 from $28.56, implying about 432% upside from the Nov. 13 closing price. The consensus remains a Buy across nine analysts, with forecasts ranging from $8 to $50 per share.American Banking and Market NewsHead-To-Head Contrast: InMed Pharmaceuticals (NASDAQ:INM) versus BioAge Labs (NASDAQ:BIOA)BioAge Labs beats InMed Pharmaceuticals on 9 of 14 factors, including analyst ratings and valuation. BioAge Labs has a consensus price target of $33.00, implying 454.62% upside, while InMed's beta is lower at 0.94. BioAge Labs plans Phase 2 trials for its lead candidate azelaprag in 2025.MarketBeatBioAge Labs, Inc. (NASDAQ:BIOA) Stock Has Consensus Price Target of $33.00BioAge Labs shares have an average analyst rating of Moderate Buy with a $33.00 price target. The company reported a loss of $0.58 per share for the quarter, beating estimates, and has a market cap of $234.09 million. Analysts predict a loss of $2.49 per share for the current fiscal year.Ticker ReportAnalyzing BioAge Labs (NASDAQ:BIOA) and Lipocine (NASDAQ:LPCN)BioAge Labs beats Lipocine on 9 of 14 factors, including higher analyst consensus and upside. BioAge Labs has a consensus target price of $33.00 versus Lipocine's $4.00, and its beta of 1.08 is higher than Lipocine's 0.4. The comparison covers profitability, valuation, and institutional ownership.Markets DailyAxsome Therapeutics (NASDAQ:AXSM) and BioAge Labs (NASDAQ:BIOA) Head to Head ContrastBioAge Labs and Axsome Therapeutics are compared on institutional ownership, valuation, earnings, and analyst ratings. Axsome has higher revenue and lower P/E, while BioAge shows higher potential upside. BioAge's STRIDES trial with tirzepatide is expected to report topline results in Q3 2025.American Banking and Market NewsGSK (NYSE:GSK) & BioAge Labs (NASDAQ:BIOA) Critical ContrastGSK and BioAge Labs are compared across analyst ratings, earnings, institutional ownership, risk, dividends, valuation, and profitability. GSK wins 7 of 13 factors, with higher revenue and earnings, while BioAge Labs has a lower P/E ratio and higher upside. BioAge Labs' STRIDES trial results are expected in Q3 2025.